More about

Car T-Cell Therapy

News
August 24, 2021
9 min read
Save

CRISPR gene editing may put universal T-cell therapy within reach

CRISPR gene editing may put universal T-cell therapy within reach

Few scientific advances have generated the optimism and enthusiasm that surround CRISPR.

News
August 24, 2021
1 min read
Save

Second-line CAR-T fails to extend EFS in aggressive B-cell non-Hodgkin lymphoma

Second-line CAR-T fails to extend EFS in aggressive B-cell non-Hodgkin lymphoma

A randomized phase 3 trial that evaluated tisagenlecleucel as second-line treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma failed to meet its primary endpoint of improved EFS, according to the agent’s manufacturer.

News
August 19, 2021
1 min read
Save

FDA clears IND application for dual-targeting CAR-T to treat advanced lymphoma

FDA clears IND application for dual-targeting CAR-T to treat advanced lymphoma

The FDA cleared an investigational new drug application for KITE-363, a chimeric antigen receptor T-cell therapy designed to treat adults with relapsed or refractory large B-cell lymphoma.

News
August 18, 2021
2 min read
Save

FDA grants orphan drug designation to allogeneic CAR-T for advanced multiple myeloma

FDA grants orphan drug designation to allogeneic CAR-T for advanced multiple myeloma

The FDA granted orphan drug designation to ALLO-715 for the treatment of advanced multiple myeloma, according to the agent’s manufacturer.

News
August 11, 2021
5 min read
Save

Remission by ’whatever means’: The role of CAR-T, HSCT for younger patients with ALL

Remission by ’whatever means’: The role of CAR-T, HSCT for younger patients with ALL

Clinicians who treat blood cancers often disagree whether chimeric antigen receptor T-cell therapies are a potential replacement for hematopoietic stem cell transplant.

News
August 10, 2021
2 min read
Save

BCMA-directed CAR-T still shows deep, durable response in heavily pretreated myeloma

Long-term results from the KarMMa trial continued to yield frequent deep and durable responses with idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in heavily pretreated patients with relapsed or refractory multiple myeloma.

News
August 10, 2021
4 min read
Save

One-step gene-editing technique opens door to safe, effective off-the-shelf CAR T cells

One-step gene-editing technique opens door to safe, effective off-the-shelf CAR T cells

CRISPR may be the most notable name in the world of gene editing, but it’s not the only option.

News
August 02, 2021
1 min read
Save

Elranatamab shows efficacy in relapsed, refractory multiple myeloma

Elranatamab shows efficacy in relapsed, refractory multiple myeloma

Subcutaneous elranatamab demonstrated efficacy and a manageable safety profile in patients with relapsed or refractory multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.

News
August 02, 2021
2 min read
Save

Neurologic adverse events manageable after CAR-T in multiple myeloma

Neurologic adverse events were generally manageable in patients with multiple myeloma after receiving ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy, according to CARTITUDE-2 data presented at the virtual ASCO Annual Meeting.

News
July 29, 2021
5 min read
Save

CAR-T for advanced lymphoma: Options do not equal choice

CAR-T for advanced lymphoma: Options do not equal choice

The FDA in February approved lisocabtagene maraleucel — a chimeric antigen receptor T cell therapy — for treatment of relapsed or refractory diffuse large B-cell lymphoma.

View more